AstraZeneca’s potential $3 billion cancer pill wins early approval
Report from Bloomberg says, a new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, won early U.S. approval on Friday, in a boost for the British drugmaker.
Tagrisso, also known as AZD9291, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on older drugs. During its defense against a takeover attempt by Pfizer last year, the firm forecast the drug could eventually sell as much as $3 billion a year.
The U.S. Food and Drug Administration (FDA) approved the once-daily tablet to treat a sub-set of patients with advanced non-small cell lung cancer four months earlier than analysts had expected.